Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis

Transl Res. 2019 Jul;209:77-89. doi: 10.1016/j.trsl.2019.02.010. Epub 2019 Feb 23.

Abstract

Systemic sclerosis (SSc, scleroderma) is a complex multisystem disease characterized by autoimmunity, vasculopathy, and most notably, fibrosis. Multiple lines of evidence demonstrate a variety of emerging cellular and molecular pathways which are relevant to fibrosis in SSc. The myofibroblast remains the key effector cell in SSc. Understanding the development, differentiation, and function of the myofibroblast is therefore crucial to understanding the fibrotic phenotype of SSc. Studies now show that (1) multiple cell types give rise to myofibroblasts, (2) fibroblasts and myofibroblasts are heterogeneous, and (3) that a large number of (primarily immune) cells have important influences on the transition of fibroblasts to an activated myofibroblasts. In SSc, this differentiation process involves multiple pathways, including well known signaling cascades such as TGF-β and Wnt/β-Catenin signaling, as well as epigenetic reprogramming and a number of more recently defined cellular pathways. After reviewing the major and emerging cellular and molecular mechanisms underlying SSc, this article looks to identify clinical applications where this new molecular knowledge may allow for targeted treatment and personalized medicine approaches.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Epigenesis, Genetic
  • Fibrosis
  • Humans
  • Myofibroblasts / pathology
  • Scleroderma, Systemic / genetics
  • Scleroderma, Systemic / immunology
  • Scleroderma, Systemic / pathology*
  • Signal Transduction
  • Skin / pathology